RAPT Therapeutics, Inc. Common Stock (RAPT) is a publicly traded Healthcare sector company. As of May 21, 2026, RAPT trades at $58.02 with a market cap of $1.68B and a P/E ratio of -18.19. RAPT moved +0.07% today. Year to date, RAPT is +132.08%; over the trailing twelve months it is +536.18%. Its 52-week range spans $5.67 to $58.02. Analyst consensus is hold with an average price target of $60.00. Rallies surfaces RAPT's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
GSK to Acquire RAPT Therapeutics for $2.2 Billion at $58 Share: GSK’s $2.2B acquisition of RAPT Therapeutics, priced at $58.00 per share, secures ozureprubart, a Phase 2b anti-IgE antibody for food allergy prophylaxis. The deal implies a notable premium to RAPT’s share price and underscores GSK’s strategic investment in immunological therapies.
| Metric | Value |
|---|---|
| Price | $58.02 |
| Market Cap | $1.68B |
| P/E Ratio | -18.19 |
| EPS | $-3.19 |
| Dividend Yield | 0.00% |
| 52-Week High | $58.02 |
| 52-Week Low | $5.67 |
| Volume | 11.13M |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $-129.87M |
| Gross Margin | 0.00% |
15 analysts cover RAPT: 0 strong buy, 4 buy, 11 hold, 0 sell, 0 strong sell. Consensus rating is hold. Average price target: $60.00.